Prurigo Nodularis Treatment Market

How Does Historic and Future Outlook For Prurigo Nodularis Treatment Market Match Up?

Initiatives such as activities and programmes undertaken for increasing the awareness about rare diseases and therapeutic options available are expected to fuel the demand for prurigo nodularis treatment. Organizations such as the National Organization for Rare Disorders (NORD) is dedicated to the offering required treatment and spreading awareness among the patients suffering from rare diseases.

Increasing advancement of technology and strategic collaboration undertaken by leading market players have paved way for innovations in prurigo nodularis treatment. For instance, in 2019 Aurobindo Pharma Ltd. has announced its decision to purchase Novartis AG unit Sandoz Inc.’s dermatology and generic pills business for US$ 1 billion leading to market expansion for prurigo nodularis treatment.

According to Future Market Insight’s analysis, the prurigo nodularis treatment market expanded at 3.8 % CAGR from 2015 to 2019.

Regions with poor economic conditions rely on the import of drugs and raw material for the treatment of prurigo nodularis. COVID 19 has led to large scale closures of manufacturing units and disruption in supply chain activities, impacting prurigo nodularis treatment market growth for the short duration of time. On the other hand, there was a significant decline in hospital-patient visits resulting in lower diagnosis in prurigo nodualris. Future Market Insights expects the global prurigo nodularis treatment market to progress at 3% CAGR through 2030.

How are the Favourable Regulations Impacting Prurigo Nodularis Treatment Demand?

Regulatory bodies are continuously trying to create favourable scenarios for the development and commercialization of orphan drugs catering to patients suffering from rare diseases. These regulations help in speeding up the development and approval process of drugs under investigation. 

For instance, the U.S. Food and Drug Administration (FDA) has dedicated Orphan Products Development (OOPD) office to advance the assessment and development of products that include drugs, biologics, medical food and devices. Hence, these favourable regulations for the development of orphan drugs are expected to boost demand for prurigo nodularis treatment market.

How is Improvement in Outpatient Services Affecting Prurigo Nodularis Treatment Market?

There has been significant funds and industry investment allocation towards developing and improving healthcare infrastructure in developing regions. As a result, there is a rising number of ambulatory care centres and dermatology clinics across the globe. This has been creating growth opportunities for the prurigo nodularis treatment market by increasing scope for diagnosis and treatment of the condition.

Clinical innovation, financial incentives and patient preferences will improve outpatient services for prurigo nodularis treatment. On the other hand, prurigo nodularis has the highest prevalence rate among patients suffering from atopic dermatitis. According to the National Eczema Association, approximately 31.6 million people across the globe suffer from atopic dermatitis. Therefore, with ease of treatment on an outpatient basis, there will be significant growth opportunities for the prurigo nodularis treatment market.

Share of drug class differs in key markets, the following chart presents the elucidated view of the drug class share concerning key regions. In the top 7 regions which include North America, Latin America, Europe, South Asia, East Asia, Oceania and the Middle East & Africa, the share of Europe is significantly high, in comparison to other regions and among drug class capsaicin cream accounts for the leading share of the market. Corticosteroids is also a mass category drug class, as it holds the second position in terms of demand across all key regions.

Country-wise Insights

How big is the Opportunity in France for Prurigo Nodularis Treatment?

Future Market Insights has projected France to remain the most lucrative market throughout the forecast period. One of the key factors supporting market expansion is the increasing prevalence of prurigo nodularis.

The increasing rate of approval and commercialization of drugs for prurigo nodularis treatment in Europe is expected to boost the market. Also, the majority of the key players have their headquarters based in Europe, which is supporting growth exhibited in the region.

France remains one of the leading countries with high-level advanced technology for diagnosis and treatment of prurigo nodularis. The market in France is expected to progress at a significant CAGR of over 3% during the forecast period.

What are the Restrains that GCC Countries Face in Prurigo Nodularis Treatment?

There is significantly less awareness about rare diseases including prurigo nodularis and its therapeutic options available in GCC countries challenging prurigo nodularis treatment market growth. On the other hand, poor economic conditions and healthcare infrastructure hinders the adoption of prurigo nodularis treatment across GCC countries. Dependency on developed countries for drug, raw materials, skilled labour and advanced technology therapeutics restraints the GCC countries prurigo nodularis treatment market growth.

Whereas, there is the increasing demand for prurigo nodularis treatment across GCC countries with increasing prevalence rate and increasing awareness campaigns/activities. The prurigo nodularis treatment market in GCC countries is expected to witness healthy growth at a CAGR of just around 5%.

What is the Contribution of U.S. in the Market of Prurigo Nodularis Treatment?

The U.S. is one of the leading countries exhibiting demand for prurigo nodularis treatment demand. The presence of highly developed healthcare infrastructure with the availability of skilled labour is driving prospects within the country. The U.S. is expected to register growth at around 2% CAGR through the forecast period. The country showcases increasing investment towards research and development activities on biopharmaceuticals aimed at developing cure of rare diseases. 

The U.S. also has been exhibiting a high rate of diagnosis and treatment adoption for prurigo nodularis as compared to other countries. The country exhibits presence of some of the leading biopharmaceutical companies and has a high rate of approval and commercialization for prurigo nodularis treatment drugs. On the other hand, it has lesser prevalence of prurigo nodularis as compared to countries in Europe, Latin America and Middle East & Africa regions.

How Attractive Is The Indian Market For Prurigo Nodularis Treatment?

There has been a significant rise in the number of domestic pharmaceutical manufacturing players in past few years in India. The Indian pharmaceutical industry is said to hold a high rank globally in terms of volume of biopharma products manufactured. The India market is set to exhibit nearly 4% CAGR over the forecast period. Some of the leading player operating in the are attracted towards investing or setting up a manufacturing plant in India due to less labour cost and high manufacturing capacities.

From past decade India has been exhibiting increasing investment towards healthcare infrastructure. Besides this, the moderate prevalence rate of prurigo nodularis and increasing treatment adoption rate are expected to fuel demand in the country.

Category-wise Insights

Why is Capsaicin Cream highly Sought-after in Prurigo Nodularis Treatment? 

Capsaicin cream accounts for over 40% of the global share among drug class through the forecast period. This is due to the increasing demand for topical drugs that are easy to apply and more effective hence capsaicin cream holds the majority of revenue share for prurigo nodularis treatment market. 

Download a Comprehensive Report Snapshot

Why is Demand for Retail Pharmacies More among Prurigo Nodularis Treatment Distribution Channel?

Revenue from retails pharmacies is expected to increase by 1.5X by 2030-end as compared to that in 2019. Easing regulatory guidelines for orphan drugs used in the treatment of prurigo nodularis is expected to boost demand for prurigo nodularis treatment market during the forecast period.

Retail pharmacies with the well-developed supply chain activities for trading across borders is the leading distribution channel for prurigo nodularis treatment market. On the other hand, with the increasing adaption of e-commerce activities, online pharmacies will observe high growth rate in the coming decade.

Competitive Landscape

Leading market players are focusing on expanding their product portfolio with strategic collaborations and product innovations. Key players are also adopting merger and acquisition strategies for increasing their presence and attracting investments across the globe in prurigo nodularis treatment market. For instance, in April 2020, VYNE Therapeutics from New Jersey released its results from two Phase 3 trials for a key product an oral drug “serlopitant” used in the treatment of prurigo nodularis. 

Some of the leading companies operating in the market are: 

• Bayer AG
• Pfizer Inc.
• GlaxoSmithKline Plc.
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Merck & Co. Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Celgene Corporation
• Galderma SA (Nestle Skin Health Company)
• VYNE Therapeutics Inc.
• Trevi Therapeutics Inc.

*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report. 

Scope of Report

Key Questions Answered in Report

• Which is the most lucrative market for prurigo nodularis treatment?

  The Europe prurigo nodularis treatment market has the highest market share. Moreover, the high prevalence of prurigo nodularis and increasing diagnosis and treatment adoption rate is creating growth for the market in Europe. France currently leads the global market for prurigo nodularis treatment, with revenue expected to reach US$ 86 Mn by 2030.

• Which drug class remains dominant for prurigo nodularis treatment?

  Capsaicin cream is expected to be most lucrative segment among the drug class with the increasing demand for easy to apply and topical therapies as compared to other drugs, and the segment is expected continue to expand at a CAGR of more than 3% over the next ten years.

• Which are some of the leading companies offering prurigo nodularis treatment? 

  Some of the leading companies offering prurigo nodularis treatment drugs are Bayer AG, Pfizer Inc., GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, Galderma SA, VYNE Therapeutics Inc., and Trevi Therapeutics, Inc.

• Which distribution channel is driving revenue of prurigo nodularis treatment market? 

  Retail pharmacies are expected to dominate the prurigo nodularis treatment market over the forecast period. On the other hand, online pharmacies will have significant growth in the coming decade with increasing adoption of e-commerce activities across the globe.

Enquiry before Buying

Is this research conducted by Future Market Insights?

Yes, the research has been conducted by expert analysts of Future Market Insights, through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Future Market Insights?

Future Market Insights follows a methodology that encompasses the demand-side assessment of the market and triangulates the same through supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions. Request a detailed methodology.

Who are the respondents for primary research?

Future Market Insights speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

What are the sources of secondary research?

Future Market Insights conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request. 

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.

How can I buy this report?

Future Market Insights provides a secure online payment system to buy reports seamlessly. You can buy the report securely and safely.

Prurigo nodularis treatment Market by Category

Drug Class

• CorticosteroidsInjectable
  • Topical
  • Oral
  • Emollients
• Capsaicin Cream
• Antihistamines
• Anticonvulsants
• Antidepressants
• Neurokinin 1 Receptor (NK1R)
• Opiate Receptor Antagonists
• Others

Distribution Channel

• Hospital Pharmacies 
• Retail Pharmacies
• Online sales

Region

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)